L-theanine is an aminoacid found in tea leaves which has relaxing effects in humans and animals. It is a structural analogue of glutamate which can bind glutamate receptors. Although the relaxing action of L-theanine has been shown in humans, laboratory animals and dogs, it has never been published in cats. The goal of this open-label, multicentre and prospective trial was to determine whether an L-theanine based oral supplement (Anxitane®, Virbac, France) could attenuate manifestations of stress in cats under field conditions. Thirty-three privately owned cats presenting signs associated with stress or fear (inappropriate urination/defecation, fear-induced aggressiveness, hypervigilance/tenseness or physical/functional manifestations of stress) for at least 1 month, were included in the study. They were given L-theanine (Anxitane®, 25 mg twice a day) for 30 days and 20 stress-related parameters were scored at Days 0, 15 and 30. The evolution of some parameters was also rated relative to Day 0. All median scores of the 20 parameters were significantly reduced at D30, and 30/33 cats (91%) had a reduced global score at the end of the study, including 21/33 with ≥50% score reduction. The median (IQR) global scores went from 18 (13–23) at D0 to 11 (8–13) at D15 and 5 (3–12) at D30 (p < 0.0001; Friedman test; significant reduction starting from D15). All the stress-related signs were significantly improved compared to D0, according to the owners, especially inappropriate elimination. Tablet palatability was judged good or very good in 94% of cases with spontaneous intake by cats when given by hand or in food. Tolerance was satisfactory as well, and no side effects were reported, so that most owners (27/33; 82%) were satisfied with the product. Despite the lack of a placebo group, it can be concluded that L-theanine (Anxitane®) helped to improve the undesirable manifestations of stress in cats in as soon as 15 days, though better results could be seen after 30 days of administration. These encouraging results show that L-theanine can help manage stress-related behaviour, but additional trials with a placebo group should be run to confirm this effect.

Muscle atrophy and weakness are prevalent and debilitating conditions in dogs that cannot be reliably prevented or treated by current approaches. In non-canine species, the natural dietary compound ursolic acid inhibits molecular mechanisms of muscle atrophy, leading to improvements in muscle health. To begin to translate ursolic acid to canine health, we developed a novel ursolic acid dietary supplement for dogs and confirmed its safety and tolerability in dogs. We then conducted a randomized, placebo-controlled, proof-of-concept efficacy study in older beagles with age-related muscle atrophy, also known as sarcopenia. Animals received placebo or ursolic acid dietary supplements once a day for 60 days. To assess the study’s primary outcome, we biopsied the quadriceps muscle and quantified atrophy-associated mRNA expression. Additionally, to determine whether the molecular effects of ursolic acid might have functional correlates consistent with improvements in muscle health, we assessed secondary outcomes of exercise participation and T-maze performance. Importantly, in canine skeletal muscle, ursolic acid inhibited numerous mRNA expression changes that are known to promote muscle atrophy and weakness. Furthermore, ursolic acid significantly improved exercise participation and T-maze performance. These findings identify ursolic acid as a natural dietary compound that inhibits molecular mechanisms of muscle atrophy and improves functional performance in dogs.

Giving dental chews to dogs is part of the passive homecare that helps prevent the formation of plaque and tartar. The objectives of these studies were to assess the effectiveness of a vegetable-based dental chew (VF) to maintain oral health, and to compare it to 2 different reference chews (RC) with a proven effectiveness. The first study was conducted on 45 small dogs (<10 kg) and the second on 60 larger dogs (15-30 kg) who were randomly assigned to 3 different groups. During 30 days, one group received no chew (control) while the second and third group received either one RC (RC1 or RC2) or one VF per day. All dogs had their teeth scaled on Day 0. On Day 30, scores were given for plaque and calculus. Gingival parameters were also assessed. Statistical analysis (analysis of variance and Tukey tests ± Bonferroni's adjustment) were performed to compare groups with α set at .05 for significance. The 3 types of chews were found to be efficacious to reduce plaque and calculus formation and the gingival bleeding compared to control (P < .05). There was no significant difference between RCs and VF in both trials except for the gingival bleeding parameters which showed a greater improvement with VF. Therefore, daily administration of the VF is effective to reduce plaque and calculus formation and gingival bleeding and has a better efficacy on gingival bleeding than the other reference products tested. It can therefore be used with confidence at home for preventative dental care.

Oral homecare plays a major part in dental disease prevention but it can be difficult to perform and time-consuming. Furthermore, the product used can be of limited efficiency. The goal of this study was to assess the efficacy of a water additive to limit the accumulation of plaque and calculus in dogs. Forty dogs were selected and randomly allocated to one of the two groups after scaling and polishing on day 0. The control group received no oral hygiene while the second group received the water additive (Vet Aquadent^® FR3SH^™, Virbac) every day. After 30 days, plaque and calculus accumulations were evaluated under anesthesia. The Gingival Bleeding Index (GBI) was assessed on days 0 and 30. On day 30, the plaque and calculus indices were significantly smaller (p < 0.05) in the Aquadent group compared to the control group with median (Q1-Q3) scores of 1.22 (0.99–1.44) vs. 2.31 (1.65–3.86), respectively for plaque and 0.25 (0.15–0.42) vs. 0.33 (0.32–0.69) for calculus. Between day 0 and day 30, the GBI significantly decreased in the control group [from 0.39 (0.21–0.56) to 0.19 (0.08–0.29)] and in the Aquadent group [from 0.33 (0.18–0.47) to 0.00 (0.00–0.00)] but the decrease was significantly greater in the Aquadent group. These results show for the first time that the water additive tested can reduce dental deposit accumulation in dogs and improve gingival health. It can be recommended after a dental cleaning, especially to owners who are reluctant to provide dental care at home due to a lack of time or convenience.

Many dental homecare products are marketed, several of which have been evaluated using a “clean tooth” protocol (the teeth are scaled at the start of the trial). The efficacy of dental products in dogs that have not had their teeth professionally cleaned (“dirty tooth model”) has been studied far less often. Some dogs for which professional dental cleaning is indicated will not have their teeth cleaned because of anesthetic risk or for other reasons. In this study, 6 dental homecare products were evaluated against a negative control group; none of the dogs received professional dental cleaning at the start of the study. The home care protocols tested were: brushing every other day using a toothpaste, feeding a dental chew once daily (VF), adding a water additive in the water daily (AQ), brushing once a week + VF daily, brushing once a week + AQ daily, VF + AQ daily. Dental deposits (plaque and calculus) and periodontal health were assessed on awake dogs, before and after receiving the assigned homecare regimen for 8 weeks. Results were compared with an untreated control group. Dental deposits were reduced by regular mechanical action (brushing or VF daily). Periodontal health status was improved when AQ daily was combined with either brushing once a week or VF daily. Two scoring techniques useful for determining a recommendation from a veterinarian to commence home oral hygiene or recommend dental scaling as a necessary first step are described.

The management of osteoarthritis (OA) in dogs is typically multimodal, including weight management, activity adjustment, joint supplements, and medical treatments when needed. This study evaluated the efficacy of a joint supplement containing eggshell membrane, krill meal with omega-3 fatty acids, Haematococcus pluvialis as a source of astaxanthin, hyaluronic acid and a Boswellia Serrata extract, in dogs with OA, in a multicenter, randomized, placebo-controlled trial. Fifty-two dogs with confirmed OA were given the test supplement or a placebo, for 90 days. Owners regularly completed two validated questionnaires for osteoarthritis (CBPI and LOAD) and rated their dog’s discomfort every 15 to 30 days. Monthly evaluations by investigators included assessments of the dog’s posture, gait, joint pain upon palpation and range of motion (from 1-normal to 4-severe or severely impacted) to determine a clinical score. Statistical analyses included both within-group and between-group comparisons. Of the 52 dogs enrolled, 46 completed the study, with 22 receiving the supplement and 24 receiving the placebo. All main parameters significantly improved over time in the supplement group (CBPI pain severity, CBPI pain interference, LOAD, discomfort, clinical score). In the placebo group, only the CBPI pain interference and LOAD improved. However, there was a statistically significant difference between groups for the CBPI pain interference (p = 0.009). Therefore, this study demonstrates that the test supplement can improve the mobility and quality of life of osteoarthritic dogs.